

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Prediction models for acute kidney injury in critical ill patients: a protocol for systematic review and critical appraisal

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046274
Article Type:	Protocol
Date Submitted by the Author:	25-Oct-2020
Complete List of Authors:	Wang, Danqiong ; Quzhou People's Hospital, Department of Critical Care Medicine Zhang, Weiwen ; Quzhou People's Hospital, Department of Critical Care Medicine Luo, Jian ; Quzhou People's Hospital, Department of Critical Care Medicine Fang, Honglong ; Quzhou People's Hospital, Department of Critical Care Medicine Jing, Shanshan ; Quzhou People's Hospital, Department of Critical Care Medicine Mei, Zubing; Shuguang Hospital, Department of Anorectal Surgery
Keywords:	Adult intensive & critical care < ANAESTHETICS, Acute renal failure < NEPHROLOGY, Risk management < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, INTENSIVE & CRITICAL CARE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Prediction models for acute kidney injury in critical ill patients: a protocol for**  
5 **systematic review and critical appraisal**  
6  
7

8  
9 Danqiong Wang<sup>1\*</sup>, Weiwen Zhang<sup>1</sup>, Jian Luo<sup>1</sup>, Honglong Fang<sup>1</sup>, Shanshan Jing<sup>1</sup>,  
10 Zubing Mei<sup>2,3\*</sup>  
11  
12

13  
14  
15  
16  
17 1. Department of Critical Care Medicine, Quzhou People's Hospital, Quzhou,  
18 Zhejiang Province, 324000, China.

19  
20  
21 2. Department of Anorectal Surgery, Shuguang Hospital, Shanghai University of  
22 Traditional Chinese Medicine, Shanghai, 201203, China

23  
24  
25 3. Anorectal Disease Institute of Shuguang Hospital, Shanghai, 201203, China.  
26  
27  
28  
29  
30

31 **Correspondence authors:**

32 Dr. Danqiong Wang, MD

33 Department of Critical Care Medicine, Quzhou People's Hospital,  
34 2 Zhongludi Road, Quzhou, Zhejiang, 324000, China.

35  
36  
37 Tel: 86 570 3056103

38  
39  
40 E-mail: danqiong.w@hotmail.com  
41

42  
43 Dr. Zubing Mei, MD, PhD

44  
45 Department of Anorectal Surgery, Shuguang Hospital, Shanghai University of  
46 Traditional Chinese Medicine; Anorectal Disease Institute of Shuguang Hospital  
47 528 Zhangheng Road, Shanghai 201203, China

48  
49  
50 Tel: 86 21 20256187

51  
52  
53 E-mail: herrmayor@126.com  
54  
55  
56

57 **Running head:** Prediction models for AKI in critical ill patients  
58  
59  
60

1  
2  
3  
4 **Abstract Word Count: 300**

5  
6 **Word Count (excluding abstract): 1700**

7  
8  
9 **References: 40**

10  
11 **Tables: 2**

12  
13  
14  
15  
16  
17 **Key words:** prediction model, acute kidney injury (AKI), critical ill, adjuvant therapy,  
18  
19 systematic review  
20  
21  
22  
23  
24  
25

26 **Funding statement:** This study was supported by the Commonweal Project of  
27  
28 Science and Technology Department of Zhejiang Province (grant no.  
29  
30 LGF19H150002), the National Natural Science Foundation of China (grant no.  
31  
32 81774112) and a grant from Siming Scholars from Shuguang Hospital (grant no.  
33  
34 SGXZ-201913).  
35  
36  
37  
38  
39  
40  
41  
42

43 **Author contributions:**

44  
45 Dr. Zubing Mei and Dr. Danqiong Wang have full access to all of the data in the  
46  
47 study and take responsibility for the integrity of the data and the accuracy of the data  
48  
49 analysis.  
50  
51

52 Study concept and design: Zubing Mei and Danqiong Wang

53  
54 Acquisition, analysis, or interpretation of data: All authors.

55  
56  
57 Drafting of the manuscript: Zubing Mei and Danqiong Wang.  
58  
59  
60

1  
2  
3  
4 Critical revision of the manuscript for important intellectual content: All authors.  
5

6 Statistical analysis: Danqiong Wang, Weiwen Zhang and Zubing Mei  
7

8  
9 Administrative, technical, or material support: All authors.  
10

11 Study supervision: Zubing Mei and Danqiong Wang  
12  
13  
14  
15  
16

17 **Competing interests statement:**  
18

19 The authors declare that they have no conflict of interest.  
20  
21  
22  
23  
24

25 **Role of the Funder/Sponsor:**  
26

27 The funder of the study had no role in the study design, data collection, data analysis,  
28  
29 data interpretation or writing of the manuscript. The corresponding author had full  
30  
31 access to all the data in the study and has final responsibility for the decision to  
32  
33 submit for publication.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Abstract**

### **Introduction**

Acute kidney injury (AKI) has high morbidity and mortality in intensive care units (ICUs), which can lead to chronic kidney disease (CKD), more costs and longer hospital stay. Early identification of AKI is crucial for clinical intervention. Though various risk prediction models have been developed to identify AKI, the overall predictive performance varies widely across studies. Due to the different disease scenarios and the small number of externally validated cohorts in different prediction models, the stability and applicability of these models for AKI in critically ill patients are controversial. The purpose of this systematic review is to map and assess prediction models for AKI in critical ill patients based on a comprehensive literature review.

### **Methods and analysis**

A systematic review with meta-analysis is designed and will be conducted according to the Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS). Three databases including Pubmed, Cochrane Library and EMBASE from inception through October 2020 will be searched to identify all studies describing development and/or external validation of original multivariable models for predicting AKI in critical ill patients.

Random-effects meta-analyses for external validation studies will be performed to estimate the performance of each model. The restricted maximum likelihood (REML)

1  
2  
3  
4 estimation and the Hartung-Knapp-Sidik-Jonkman (HKSJ) method under a  
5  
6 random-effects model will be applied to estimate the summary C statistic and 95% CI.  
7  
8  
9 95% prediction interval (PI) integrating the heterogeneity will also be calculated to  
10  
11 pool C-statistics to predict a possible range of C-statistics of future validation studies.  
12  
13  
14 Two investigators will extract data independently using the CHARMS checklist.  
15  
16  
17 Study quality or risk of bias will be assessed using the Prediction Model Risk of Bias  
18  
19 Assessment Tool (PROBAST).  
20  
21  
22  
23  
24

### 25 **Ethics and dissemination**

26  
27 Ethical approval and patient informed consent are not required because all  
28  
29 information will be abstracted from published literatures. We plan to share our results  
30  
31 with clinicians and publish them in a general or critical care medicine peer- reviewed  
32  
33 journal. We also plan to present our results at critical care international conferences.  
34  
35  
36  
37  
38  
39

40 **OSF registration number** 10.17605/OSF.IO/X25AT  
41  
42  
43  
44

### 45 **Key words**

46  
47  
48 Prediction model; acute kidney injury (AKI); critical ill; systematic review; cohort  
49  
50  
51 study  
52  
53  
54  
55  
56  
57  
58  
59  
60



### Strengths and limitations of this study

- This study will provide an overall mapping of the available studies on prediction models for acute kidney injury (AKI) in critical ill patients.
- This study will be carried out and reported according to the Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).
- Prediction models for AKI in critical ill patients will be evaluated using the PROBAST tool.
- Meta-analysis of C statistics will be conducted for prediction models that are externally validated in different individual populations.
- Several potential sources of heterogeneity including the differences in clinical scenarios, patients' characteristics, cohort regions or races and statistical methods will need further investigation.

## **Introduction**

Acute kidney injury (AKI) is a common condition among hospitalized critical patients, especially in intensive care units (ICUs), and has been a major healthcare burden worldwide.<sup>1-4</sup> AKI is also associated with serious complications, increased health care costs, length of stay and mortality. More than 1.7 million deaths have been reported indirectly due to AKI annually related to chronic kidney disease (CKD), cardiovascular and cerebrovascular events.<sup>5-8</sup>

AKI can originate from heterogeneous causes, and stratifying cases according to characteristics and biomarkers would raise possibility of early prediction of AKI. Biomarkers including serum creatinine (sCr) and urine output are commonly used ones to define AKI.<sup>9</sup> More recently, several other frequently used and new candidate biomarkers have been found to predict AKI in clinics at different stage of the disease condition, but many of them are found to have low sensitivity and specificity.<sup>10-16</sup>

Clinical prediction models are widely used in real-world clinical practice. They are proved to be useful for informing healthcare systems to distinguish high risk patients, guide diagnostic and therapeutic intervention selection, thus early measurements could be taken to improve outcomes.<sup>17</sup> The application of multidimensional indicators to predict the risk of AKI in critical ill patients may provide a more comprehensive approach of disease assessment. Furthermore, in

1  
2  
3  
4 critically ill patients, multivariable risk prediction models for AKI could be used in  
5  
6 clinical practice to assist decision making on hospital admission or admission to ICUs  
7  
8  
9 and treatment options.<sup>18-20</sup>  
10

11  
12  
13  
14 Several prediction models, incorporating multiple predictors for the prediction  
15  
16 of AKI, have been developed. Wang et al found that hypertension, chronic kidney  
17  
18 disease, acute pancreatitis, cardiac failure, shock,  $\text{pH} \leq 7.30$ , creatine kinase (CK)  $>$   
19  
20 1000 U/L, hypoproteinemia, nephrotoxin exposure, and male gender were  
21  
22 independent predictors of AKI.<sup>21</sup> Ferrari and colleagues established a novel prediction  
23  
24 score to quickly predict AKI at any stage up to 7 days.<sup>22</sup> However, to the best of our  
25  
26 knowledge, no prognostic model for AKI has been endorsed. In routine clinical  
27  
28 practice, no a standardised prediction model have been widely accepted or routinely  
29  
30 been used.  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 In this study, we aim to systematically summarise the reported multivariable  
41  
42 models developed for predicting AKI in critically ill patients, to map their  
43  
44 characteristics and laboratory features, and to test whether they have been carried out  
45  
46 external validation. We will apply the Prediction Model Risk of Bias Assessment  
47  
48 Tool (PROBAST) to assess the risk of bias of the methodological aspects of the  
49  
50 included studies developing or validating prediction models. For prediction models  
51  
52 involving several validation studies, we will perform a  $\chi^2$  for performance  
53  
54 and calibration of each model to yield more accurate effect estimates.  
55  
56  
57  
58  
59  
60

## METHODS AND ANALYSIS

We will design and conduct this systematic review according to Preferred Reporting Items for Systematic Review and Meta-Analyses Protocol (PRISMA-P) guideline<sup>23</sup> and the Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS)<sup>24</sup> and the guidance by Debray et al.<sup>25</sup> We have registered the protocol on the website of open science framework (OSF) (<https://osf.io/x25at/>).

### Literature search

We systematically searched PubMed, Embase and Cochrane Library from inception to October 2020 to capture all relevant studies developing and/or validating a prediction model for AKI in critically ill patients. The following search strategy with related key words was developed: (predict\* OR progn\* OR “risk prediction” OR “risk score” OR “risk calculation” OR “risk assessment” OR “C statistic” OR discrimination OR calibration OR AUC OR “area under the curve” OR “area under the receiver operator characteristic curve”) AND (“acute kidney failure” OR “acute tubular necrosis” OR “acute kidney tubule necrosis” OR AKI OR ARI OR AKF OR ARF) AND (“emergency care unit” OR “intensive care unit” OR “critical ill patient” OR “acute ill\*” OR ICU). Two independent investigators will undertake the literature search and screening, and discrepancies will be resolved by a senior author. We will

1  
2  
3  
4 further hand search the reference list of each eligible study for potential missing  
5  
6 eligible studies.  
7  
8  
9

## 10 11 **Eligibility criteria**

12  
13  
14 We will include all cohort studies that described development and external  
15  
16 validation of original multivariable models for predicting AKI in critical ill patients.

17  
18 We present the detailed description of the PICOTS for this systematic review in Table

19  
20  
21 1. Based on the Transparent Reporting of a multivariable prediction model for  
22  
23 Individual Prognosis Or Diagnosis (TRIPOD) guideline,<sup>26</sup> we will screen and select  
24  
25 eligible prognostic model studies when the following inclusion criteria are satisfied.  
26  
27

28  
29 1) studies that reported the development or validation multivariable model(s) of AKI  
30  
31 with or without external validation; 2) studies that yielded at least two predictors; 3)  
32  
33 studies that evaluated or updated the quantitative measure of model performance of an  
34  
35 existing model in an independent population in terms of overall performance,  
36  
37 discriminative ability and calibration of a certain prediction model. We will exclude  
38  
39 conference abstracts, editorials, clinical case reviews, letters, commentaries, book  
40  
41 chapters and surveys.  
42  
43  
44  
45  
46  
47  
48  
49

## 50 51 **Data abstraction**

52  
53 Data extraction will be conducted using a standardised data extraction form by  
54  
55 at least two independently reviewers based on the recommendations in the CHARMS  
56  
57 checklist.<sup>24</sup> If the needed data are not reported or unclear, the corresponding authors  
58  
59  
60

1  
2  
3  
4 will be contacted for detailed information. The following general  
5  
6 study information will be extracted including first author, publication year, model  
7  
8 name, publication source and research country. For model development study, we will  
9  
10 extract the following specific data: modelling method, method for selection of  
11  
12 predictors for inclusion in multivariable modeling combined with criteria used and  
13  
14 shrinkage of predictor weights or regression coefficients. For model performance  
15  
16 study, measures of calibration and discrimination with confidence intervals will be  
17  
18 abstracted. For studies reporting model evaluation, method used for testing model  
19  
20 performance will also be abstracted. Besides, the method for treating the missing data  
21  
22 involving the prediction model of each eligible study will also be abstracted.  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **Critical appraisal**

32  
33 We will critically appraise each included prediction model using the PROBAST  
34  
35 technique, a tool to assess risk of bias and applicability of prediction model studies.<sup>27</sup>  
36  
37 Based on the checklist of PROBAST, 20 separate questions across 4 domains  
38  
39 (participants, predictors, outcome, and analysis) will be asked. Details for the  
40  
41 assessment rules are summarized in Table 2. Two authors of the research team will  
42  
43 independently assess the risk of bias of the included studies and cross-check the  
44  
45 results. Any discrepancies will be resolved by discussion or by a senior author.  
46  
47  
48  
49  
50  
51  
52  
53  
54

### 55 **Statistical analysis**

56  
57 We will calculate and report descriptive statistics to summarise the characteristics of  
58  
59 the AKI models. For binary or categorical variables, we will calculate frequencies or  
60

1  
2  
3  
4 percentages, while for continuous variables, means, medians, and interquartile ranges  
5  
6 (IQRs) will be calculated. For the prediction model of AKI developed from different  
7  
8 populations, a random effects  $I^2$  will be applied to calculate a summary  
9  
10 estimate for models' performance and calibration. For studies that did not provide  
11  
12 measurements of mean C statistics, we will use a formula to estimate the standard  
13  
14 error of mean C statistic according to the methods proposed by Snell and colleagues.<sup>28</sup>  
15  
16 Due to the relatively small sample size of validation studies for each prediction model,  
17  
18 we will meta-analyse C statistic with its 95% CI using a random-effects model based  
19  
20 on the restricted maximum likelihood (REML) estimation and the  
21  
22 Hartung-Knapp-Sidik-Jonkman (HKSJ) method.<sup>25 29</sup> 95% prediction interval (PI)  
23  
24 integrating the heterogeneity will also be calculated to pool C statistics to predict a  
25  
26 possible range of C statistics of future validation studies. Heterogeneity between  
27  
28 studies will be quantified using the  $I^2$  statistic, defined significant heterogeneity when  
29  
30  $I^2$  statistic more than 50%.<sup>30</sup> The potential of publication bias will be assessed by  
31  
32 funnel plots when more than 10 studies are meta-analysed for the prediction model.  
33  
34 All statistical analyses will be carried out using R Statistical Software version 3.2.3(R  
35  
36 Core Team, R Foundation for Statistical Computing, Vienna, Austria) and Stata  
37  
38 version 15.0 (Stata Corporation, College Station, TX, USA).  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

### 53 **Patient and public involvement**

54  
55 The current study is a systematic review of what is already reported in the literature. It  
56  
57 does not involve patient and public in the design, conduct or reporting of this study.  
58  
59  
60

## **Ethics and dissemination**

Ethical approval and patient informed consent are not required because all information will be abstracted from published literatures. We plan to share our results with clinicians and publish them in a general or critical care medicine peer-reviewed journal. We also plan to present our results at critical care international conferences.

## **Amendments**

The protocol for this systematic review will be amended when necessary during the peer-review process.

## **DISCUSSION**

Although there have been numerous original reports and narrative reviews focusing on the prediction model of AKI,<sup>31-39</sup> several factors may limit the interpretation and application of these prediction models. To the best of our knowledge, this will be the first systematic review that aims to evaluate the published evidence on the prediction models for AKI. This study will provide a clear overview for clinicians to identify some most effective prediction models for AKI among critical ill patients or patients in ICUs. By synthesising data including predictive accuracy such as C statistics across studies, we may get some evidence-based data to stratify disease severity and help inform the clinical management of critical ill patients.



## Strengths and limitations

There will be several strengths of this study. Firstly, we will strictly adhere to the Cochrane Handbook's method recommendations during the conduct and reporting of this systematic review to make the results more reliable.<sup>25 40</sup> The purpose of this study is to achieve high-quality evidence regarding the prediction model of AKI in critical ill patients and provide practice recommendations on its applicability for policy makers. Secondly, we will present a detailed description of the characteristics of the reported prediction models for AKI. Moreover, another important strength is the critical appraisal of prediction models for AKI by using the PROBAST tool. Finally, we will perform a  $\chi^2$  and C statistics for prediction models that are externally validated in different independent cohorts.

There are also limitations to this study. One is that large between study heterogeneity is expected in the meta-analyses. There may be several potential sources of heterogeneity including the differences in clinical scenarios, patients' characteristics, cohort regions or races and statistical methods. However, due to the small number of development or validation studies, subgroup analyses or meta-regression analyses cannot be performed.

In summary, this study will provide an overall mapping of the available research on prediction models for AKI in critical ill patients.

## References

1. Thongprayoon C, Cheungpasitporn W, Chewcharat A, et al. Impact of admission serum ionized calcium levels on risk of acute kidney injury in hospitalized patients. *Scientific reports* 2020;10(1):12316. doi: 10.1038/s41598-020-69405-0 [published Online First: 2020/07/25]
2. Levey AS, James MT. Acute Kidney Injury. *Annals of internal medicine* 2017;167(9):Itc66-itc80. doi: 10.7326/aitc201711070 [published Online First: 2017/11/09]
3. Zuk A, Bonventre JV. Acute Kidney Injury. *Annual review of medicine* 2016;67:293-307. doi: 10.1146/annurev-med-050214-013407 [published Online First: 2016/01/16]
4. Zeng X, McMahon GM, Brunelli SM, et al. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. *Clinical journal of the American Society of Nephrology : CJASN* 2014;9(1):12-20. doi: 10.2215/cjn.02730313 [published Online First: 2013/11/02]
5. Varrier M, Forni LG, Ostermann M. Long-term sequelae from acute kidney injury: potential mechanisms for the observed poor renal outcomes. *Critical care (London, England)* 2015;19(1):102. doi: 10.1186/s13054-015-0805-0 [published Online First: 2015/04/19]
6. Soliman IW, Frencken JF, Peelen LM, et al. The predictive value of early acute kidney injury for long-term survival and quality of life of critically ill patients. *Critical care (London, England)* 2016;20(1):242. doi: 10.1186/s13054-016-1416-0 [published Online First: 2016/08/05]
7. Doyle JF, Forni LG. Acute kidney injury: short-term and long-term effects. *Critical care (London, England)* 2016;20(1):188. doi: 10.1186/s13054-016-1353-y [published Online First: 2016/07/05]
8. An JN, Hwang JH, Kim DK, et al. Chronic Kidney Disease After Acute Kidney Injury Requiring Continuous Renal Replacement Therapy and Its Impact on Long-Term Outcomes: A Multicenter Retrospective Cohort Study in Korea. *Critical care medicine* 2017;45(1):47-57. doi: 10.1097/ccm.0000000000002012 [published Online First: 2016/08/27]
9. AKIWG K. Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for acute kidney injury. *Kidney inter* 2012;2(Suppl):1-138.
10. Sandokji I, Greenberg JH. Novel biomarkers of acute kidney injury in children: an update on recent findings. *Current Opinion in Pediatrics* 2020;32(3):354-59.
11. Peng Z-Y. The biomarkers for acute kidney injury: A clear road ahead? *Journal of Translational Internal Medicine* 2016;4(3):95-98.
12. Oh D-J. A long journey for acute kidney injury biomarkers. *Renal Failure* 2020;42(1):154-65.

13. Griffin BR, Gist KM, Faubel S. Current status of novel biomarkers for the diagnosis of acute kidney injury: a historical perspective. *Journal of intensive care medicine* 2020;35(5):415-24.
14. Devarajan P. Emerging biomarkers of acute kidney injury. *Acute Kidney Injury*: Karger Publishers 2007:203-12.
15. Askenazi DJ, Koralkar R, Hundley HE, et al. Urine biomarkers predict acute kidney injury in newborns. *The Journal of pediatrics* 2012;161(2):270-75. e1.
16. Arthur JM, Hill EG, Alge JL, et al. Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery. *Kidney international* 2014;85(2):431-38.
17. Altman DG, Royston P. What do we mean by validating a prognostic model? *Statistics in medicine* 2000;19(4):453-73.
18. İZBİR, ÖRS, TAY, Çukurova Z, Özel Bilgi D, et al. Prognostic Impact of Early Versus Late Initiation of Renal Replacement Therapy Based on Early Warning Algorithm in Critical Care Patients With Acute Kidney Injury. *Therapeutic Apheresis and Dialysis* 2020;24(4):445-52.
19. Lazzeri C, Bonizzoli M, Cianchi G, et al. The prognostic role of peak glycemia and glucose variability in trauma: a single-center investigation. *Acta Diabetologica* 2020:1-5.
20. Haniffa R, Mukaka M, Munasinghe SB, et al. Simplified prognostic model for critically ill patients in resource limited settings in South Asia. *Critical Care* 2017;21(1):250.
21. Wang Q, Tang Y, Zhou J, et al. A prospective study of acute kidney injury in the intensive care unit: development and validation of a risk prediction model. *Journal of translational medicine* 2019;17(1):359.
22. Ferrari F, Puci MV, Ferraro OE, et al. Development and validation of quick Acute Kidney Injury-score (q-AKI) to predict acute kidney injury at admission to a multidisciplinary intensive care unit. *PloS one* 2019;14(6):e0217424.
23. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic reviews* 2015;4(1):1.
24. Moons KG, de Groot JA, Bouwmeester W, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. *PLoS Med* 2014;11(10):e1001744.
25. Debray TP, Damen JA, Snell KI, et al. A guide to systematic review and meta-analysis of prediction model performance. *BMJ (Clinical research ed)* 2017;356:i6460.
26. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Annals of internal medicine* 2015;162(1):W1-W73.
27. Moons KG, Wolff RF, Riley RD, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. *Annals of internal medicine* 2019;170(1):W1-W33.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
28. Snell KI, Ensor J, Debray TP, et al. Meta-analysis of prediction model performance across multiple studies: Which scale helps ensure between-study normality for the C-statistic and calibration measures? *Statistical methods in medical research* 2018;27(11):3505-22.
29. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. *BMC medical research methodology* 2014;14(1):25.
30. Rücker G, Schwarzer G, Carpenter JR, et al. Undue reliance on I<sup>2</sup> in assessing heterogeneity may mislead. *BMC medical research methodology* 2008;8(1):79.
31. Porter CJ, Moppett IK, Juurlink I, et al. Acute and chronic kidney disease in elderly patients with hip fracture: prevalence, risk factors and outcome with development and validation of a risk prediction model for acute kidney injury. *BMC nephrology* 2017;18(1):20.
32. Kalisvaart M, Schlegel A, Umbro I, et al. The AKI Prediction Score: a new prediction model for acute kidney injury after liver transplantation. *HPB* 2019;21(12):1707-17.
33. Tomašev N, Glorot X, Rae JW, et al. A clinically applicable approach to continuous prediction of future acute kidney injury. *Nature* 2019;572(7767):116-19.
34. Motwani SS, McMahon GM, Humphreys BD, et al. Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. *Journal of Clinical Oncology* 2018;36(7):682.
35. Koyner JL, Carey KA, Edelson DP, et al. The development of a machine learning inpatient acute kidney injury prediction model. *Critical care medicine* 2018;46(7):1070-77.
36. Laszczynska O, Severo M, Azevedo A. Electronic medical record-based predictive model for acute kidney injury in an acute care hospital. *Studies in health technology and informatics, vol 228, p 810-812* 2016
37. Pannu N, Graham M, Klarenbach S, et al. A new model to predict acute kidney injury requiring renal replacement therapy after cardiac surgery. *CMAJ* 2016;188(15):1076-83.
38. Piñana JL, Perez-Pitarch A, Garcia-Cadenas I, et al. A time-to-event model for acute kidney injury after reduced-intensity conditioning stem cell transplantation using a tacrolimus-and sirolimus-based graft-versus-host disease prophylaxis. *Biology of Blood and Marrow Transplantation* 2017;23(7):1177-85.
39. Tsai TT, Patel UD, Chang TI, et al. Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath - PCI Registry. *Journal of the American Heart Association* 2014;3(6):e001380.
40. Higgins JP, Thomas J, Chandler J, et al. *Cochrane handbook for systematic reviews of interventions*: John Wiley & Sons 2019.

## Tables and legends

**Table 1.** Primary elements for formulating study purpose, search strategy, inclusion and exclusion criteria for the study according to the following PICOTS guidance

Item	Definition
Population	Patients who were critically ill
Intervention	Any prediction model to predict the risk of acute kidney injury (AKI) in patients with critical illness, to distinguish critical ill patients with poor outcome (who will develop AKI), or to aid in clinical decision making in acute care, planning therapeutic intervention and monitoring treatment response
Comparator	Not applicable
Outcomes	AKI reported by prediction models
Timing	Predictive variables measured at any timepoint during the clinical course of the disease; no specific limitation applied in prediction horizon
Setting	Patients with critical illness who were admitted to hospital, treated in intensive care unit (ICU), or emergency department

1  
2  
3  
4 **Table 2.** Twenty key questions assessing the risk of bias for 4 domains of participants,  
5  
6 predictors, outcome and analysis.  
7

---

### 8 **Domain 2: Participants**

---

9  
10  
11 1.1 Were appropriate data sources used, e.g., cohort, RCT, or nested case-control  
12  
13 study data?  
14

15  
16  
17 1.2 Were all inclusions and exclusions of participants appropriate?  
18

---

### 19 **Domain 2: Predictors**

---

20  
21  
22 2.1 Were predictors defined and assessed in a similar way for all participants?  
23

24  
25 2.2 Were predictor assessments made without knowledge of outcome data?  
26

27  
28 2.3 Are all predictors available at the time the model is intended to be used?  
29

---

### 30 **Domain 3: Outcome**

---

31  
32  
33 3.1 Was the outcome determined appropriately?  
34

35  
36 3.2 Was a prespecified or standard outcome definition used?  
37

38  
39 3.3 Were predictors excluded from the outcome definition?  
40

41  
42 3.4 Was the outcome defined and determined in a similar way for all participants?  
43

44  
45 3.5 Was the outcome determined without knowledge of predictor information?  
46

47  
48 3.6 Was the time interval between predictor assessment and outcome determination  
49 appropriate?  
50

---

### 51 **Domain 4: Analysis**

---

52  
53  
54 4.1 Were there a reasonable number of participants with the outcome?  
55

56  
57 4.2 Were continuous and categorical predictors handled appropriately?  
58

59  
60 4.3 Were all enrolled participants included in the analysis?  
61

---

---

1  
2  
3  
4 4.4 Were participants with missing data handled appropriately?  
5  
6

7 4.5 Was selection of predictors based on univariable analysis avoided?  
8

9 4.6 Were complexities in the data (e.g., censoring, competing risks, sampling of  
10 control participants) accounted for appropriately?  
11

12 4.7 Were relevant model performance measures evaluated appropriately?  
13

14 4.8 Were model overfitting and optimism in model performance accounted for?  
15

16 4.9 Do predictors and their assigned weights in the final model correspond to the  
17 results from the reported multivariable analysis?  
18  
19  
20  
21  
22  
23

---

# BMJ Open

## Prediction models for acute kidney injury in critical ill patients: a protocol for systematic review and critical appraisal

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046274.R1
Article Type:	Protocol
Date Submitted by the Author:	07-Apr-2021
Complete List of Authors:	Wang, Danqiong ; Quzhou People's Hospital, Department of Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University Zhang, Weiwen ; Quzhou People's Hospital, Department of Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University Luo, Jian ; Quzhou People's Hospital, Department of Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University Fang, Honglong ; Quzhou People's Hospital, Department of Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University Jing, Shanshan ; Quzhou People's Hospital, Department of Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University Mei, Zubing; Shuguang Hospital, Department of Anorectal Surgery; Anorectal Disease Institute of Shuguang Hospital, Shanghai University of Traditional Chinese Medicine
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Evidence based practice
Keywords:	Adult intensive & critical care < ANAESTHETICS, Acute renal failure < NEPHROLOGY, Risk management < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, INTENSIVE & CRITICAL CARE

SCHOLARONE™  
Manuscripts





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Prediction models for acute kidney injury in critical ill patients: a protocol for**  
5 **systematic review and critical appraisal**  
6  
7

8  
9 Danqiong Wang<sup>1\*</sup>, Weiwen Zhang<sup>1</sup>, Jian Luo<sup>1</sup>, Honglong Fang<sup>1</sup>, Shanshan Jing<sup>1</sup>,  
10 Zubing Mei<sup>2,3\*</sup>  
11  
12

13  
14  
15  
16  
17 1. Department of Critical Care Medicine, The Quzhou Affiliated Hospital of  
18 Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang Province,  
19 324000, China.  
20  
21

22  
23 2. Department of Anorectal Surgery, Shuguang Hospital, Shanghai University of  
24 Traditional Chinese Medicine, Shanghai, 201203, China  
25  
26

27 3. Anorectal Disease Institute of Shuguang Hospital, Shanghai, 201203, China.  
28  
29  
30  
31  
32

33 **Correspondence authors:**

34 Dr. Danqiong Wang, MD

35 Department of Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou  
36 Medical University, Quzhou People's Hospital,  
37 2 Zhongludi Road, Quzhou, Zhejiang, 324000, China.  
38  
39

40 Tel: 86 570 3056103

41 E-mail: danqiong.w@hotmail.com  
42  
43  
44  
45

46 Dr. Zubing Mei, MD, PhD

47 Department of Anorectal Surgery, Shuguang Hospital, Shanghai University of  
48 Traditional Chinese Medicine; Anorectal Disease Institute of Shuguang Hospital  
49 528 Zhangheng Road, Shanghai 201203, China  
50  
51

52 Tel: 86 21 20256187  
53  
54

55 E-mail: herrmayor@126.com or herrmayor@shutcm.edu.cn  
56  
57  
58  
59  
60

1  
2  
3  
4 **Running head:** Prediction models for AKI in critical ill patients  
5  
6  
7

8  
9 **Abstract Word Count:** 300  
10

11 **Word Count (excluding abstract):** 1889  
12

13  
14 **References:** 44  
15

16  
17 **Tables:** 2  
18

19  
20  
21  
22 **Funding statement:** This study was supported by the Commonweal Project of  
23  
24 Science and Technology Department of Zhejiang Province (grant no.  
25  
26 LGF19H150002), the National Natural Science Foundation of China (grant no.  
27  
28 81774112) and a grant from Siming Scholars from Shuguang Hospital (grant no.  
29  
30 SGXZ-201913).  
31  
32  
33  
34  
35  
36  
37  
38

39 **Author contributions:**

40  
41 Dr. Zubing Mei and Dr. Danqiong Wang have full access to all of the data in the  
42  
43 study and take responsibility for the integrity of the data and the accuracy of the data  
44  
45 analysis.  
46  
47

48  
49 Study concept and design: Zubing Mei and Danqiong Wang

50  
51 Acquisition, analysis, or interpretation of data: Danqiong Wang, Weiwen Zhang, Jian  
52  
53 Luo, Honglong Fang, Shanshan Jing, and Zubing Mei.  
54  
55

56  
57 Drafting of the manuscript: Zubing Mei and Danqiong Wang.  
58  
59  
60

1  
2  
3  
4 Critical revision of the manuscript for important intellectual content: Danqiong Wang,

5  
6 Weiwen Zhang, Jian Luo, Honglong Fang, Shanshan Jing, and Zubing Mei.

7  
8  
9 Statistical analysis: Danqiong Wang, Weiwen Zhang and Zubing Mei

10  
11 Administrative, technical, or material support: All authors.

12  
13  
14 Study supervision: Zubing Mei and Danqiong Wang

15  
16  
17  
18  
19 **Competing interests statement:**

20  
21  
22 The authors declare that they have no conflict of interest.

23  
24  
25  
26  
27 **Role of the Funder/Sponsor:**

28  
29  
30 The funder of the study had no role in the study design, data collection, data analysis,  
31  
32 data interpretation or writing of the manuscript. The corresponding author had full  
33  
34 access to all the data in the study and has final responsibility for the decision to  
35  
36 submit for publication.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Abstract**

### **Introduction**

Acute kidney injury (AKI) has high morbidity and mortality in intensive care units (ICUs), which can lead to chronic kidney disease (CKD), more costs and longer hospital stay. Early identification of AKI is crucial for clinical intervention. Though various risk prediction models have been developed to identify AKI, the overall predictive performance varies widely across studies. Due to the different disease scenarios and the small number of externally validated cohorts in different prediction models, the stability and applicability of these models for AKI in critically ill patients are controversial. Moreover, there are no current risk-classification tools that are standardised for prediction of AKI in critically ill patients. The purpose of this systematic review is to map and assess prediction models for AKI in critical ill patients based on a comprehensive literature review.

### **Methods and analysis**

A systematic review with meta-analysis is designed and will be conducted according to the Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS). Three databases including Pubmed, Cochrane Library and EMBASE from inception through October 2020 will be searched to identify all studies describing development and/or external validation of original multivariable models for predicting AKI in critical ill patients.

Random-effects meta-analyses for external validation studies will be performed to

1  
2  
3  
4 estimate the performance of each model. The restricted maximum likelihood (REML)  
5  
6 estimation and the Hartung-Knapp-Sidik-Jonkman (HKSJ) method under a  
7  
8 random-effects model will be applied to estimate the summary C statistic and 95% CI.  
9  
10 95% prediction interval (PI) integrating the heterogeneity will also be calculated to  
11  
12 pool C-statistics to predict a possible range of C-statistics of future validation studies.  
13  
14  
15 Two investigators will extract data independently using the CHARMS checklist.  
16  
17  
18 Study quality or risk of bias will be assessed using the Prediction Model Risk of Bias  
19  
20 Assessment Tool (PROBAST).  
21  
22  
23  
24  
25  
26  
27

### 28 **Ethics and dissemination**

29  
30 Ethical approval and patient informed consent are not required because all  
31  
32 information will be abstracted from published literatures. We plan to share our results  
33  
34 with clinicians and publish them in a general or critical care medicine peer- reviewed  
35  
36 journal. We also plan to present our results at critical care international conferences.  
37  
38  
39  
40  
41  
42

43 **OSF registration number** 10.17605/OSF.IO/X25AT  
44  
45  
46  
47

### 48 **Key words**

49  
50 Prediction model; acute kidney injury (AKI); critical ill; systematic review; cohort  
51  
52 study  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of this study

- This study will provide an overall mapping of the available studies on prediction models for acute kidney injury (AKI) in critical ill patients.
- This study will be carried out and reported according to the Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).
- Prediction models for AKI in critical ill patients will be evaluated using the PROBAST tool.
- Meta-analysis of C statistics will be conducted for prediction models that are externally validated in different individual populations.
- Several potential sources of heterogeneity including AKI definition, AKI type, window of prediction and other study characteristics will need further investigation.

## **Introduction**

Acute kidney injury (AKI) is a common condition among hospitalized critical patients, especially in intensive care units (ICUs), and has been a major healthcare burden worldwide.<sup>1-4</sup> AKI is also associated with serious complications, increased health care costs, length of stay and mortality. More than 1.7 million deaths have been reported indirectly due to AKI annually related to chronic kidney disease (CKD), cardiovascular and cerebrovascular events.<sup>5-8</sup>

AKI can originate from heterogeneous causes, and stratifying cases according to characteristics and biomarkers would raise possibility of early prediction of AKI. Currently, there is a great need for multi-modal data in the development of these models as the clinical trajectory of critical illness involves multiple organ dysfunction and organ cross-talk, which can be captured with different data types. Biomarkers including serum creatinine (sCr) and urine output are commonly used ones to define AKI.<sup>9</sup> More recently, several other frequently used and new candidate biomarkers have been found to predict AKI in clinics at different stage of the disease condition, but many of them are found to have low sensitivity and specificity.<sup>10-16</sup>

Clinical prediction models are widely used in real-world clinical practice. They are proved to be useful for informing healthcare systems to distinguish high risk patients, guide diagnostic and therapeutic intervention selection, thus early measurements could be taken to improve outcomes.<sup>17</sup> The application of



1  
2  
3  
4 multidimensional indicators to predict the risk of AKI in critical ill patients may  
5  
6 provide a more comprehensive approach of disease assessment. Furthermore, in  
7  
8 critically ill patients, multivariable risk prediction models for AKI could be used in  
9  
10 clinical practice to assist decision making on hospital admission or admission to ICUs  
11  
12 and treatment options.<sup>18-20</sup>  
13  
14  
15  
16  
17  
18  
19

20 Several prediction models, incorporating multiple predictors for the prediction  
21  
22 of AKI, have been developed. Wang et al found that hypertension, chronic kidney  
23  
24 disease, acute pancreatitis, cardiac failure, shock,  $\text{pH} \leq 7.30$ , creatine kinase (CK) >  
25  
26 1000 U/L, hypoproteinemia, nephrotoxin exposure, and male gender were  
27  
28 independent predictors of AKI.<sup>21</sup> Ferrari and colleagues established a novel prediction  
29  
30 score to quickly predict AKI at any stage up to 7 days.<sup>22</sup> However, to the best of our  
31  
32 knowledge, no prognostic model for AKI has been endorsed. Moreover, in routine  
33  
34 clinical practice, there are no current risk-classification tools that are standardised for  
35  
36 prediction of AKI in critically ill patients.  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 In this study, we aim to systematically summarise the reported multivariable  
47  
48 models developed for predicting AKI in critically ill patients, to map their  
49  
50 characteristics and laboratory features, and to test whether they have been carried out  
51  
52 external validation. We will apply the Prediction Model Risk of Bias Assessment  
53  
54 Tool (PROBAST) to assess the risk of bias of the methodological aspects of the  
55  
56 included studies developing or validating prediction models. For prediction models  
57  
58  
59  
60

1  
2  
3  
4 involving several validation studies, we will perform a meta-analysis for performance  
5  
6 and calibration of each model to yield more accurate effect estimates.  
7  
8  
9

## 10 11 **METHODS AND ANALYSIS**

12  
13  
14 We will design and conduct this systematic review according to Preferred  
15  
16 Reporting Items for Systematic Review and Meta-Analyses Protocol (PRISMA-P)  
17  
18 guideline<sup>23</sup> and the Checklist for critical Appraisal and data extraction for systematic  
19  
20 Reviews of prediction Modelling Studies (CHARMS)<sup>24</sup> and the guidance by Debray  
21  
22 et al.<sup>25</sup> We have registered the protocol on the website of open science framework  
23  
24 (OSF) (<https://osf.io/x25at/>).  
25  
26  
27  
28  
29  
30  
31

### 32 **Literature search**

33  
34 We systematically searched PubMed, Embase and Cochrane Library from  
35  
36 inception to October 2020 to capture all relevant studies developing and/or validating  
37  
38 a prediction model for AKI in critically ill patients. The following search strategy  
39  
40 with related key words was developed: (predict\* OR progn\* OR “risk prediction” OR  
41  
42 “risk score” OR “risk calculation” OR “risk assessment” OR “C statistic” OR  
43  
44 discrimination OR calibration OR AUC OR “area under the curve” OR “area under  
45  
46 the receiver operator characteristic curve”) AND (“acute kidney failure” OR “acute  
47  
48 tubular necrosis” OR “acute kidney tubule necrosis” OR AKI OR ARI OR AKF OR  
49  
50 ARF) AND (“emergency care unit” OR “intensive care unit” OR “critical ill patient”  
51  
52 OR “acute ill\*” OR ICU). Two independent investigators will undertake the literature  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 search and screening, and discrepancies will be resolved by a senior author. We will  
5  
6 further hand search the reference list of each eligible study for potential missing  
7  
8 eligible studies.  
9  
10

### 11 12 13 14 **Eligibility criteria**

15  
16 We will include all cohort studies that described development and external  
17  
18 validation of original multivariable models for predicting AKI in critical ill patients.  
19

20 We present the detailed description of the PICOTS for this systematic review in Table

21  
22 1. Based on the Transparent Reporting of a multivariable prediction model for  
23  
24 Individual Prognosis Or Diagnosis (TRIPOD) guideline,<sup>26</sup> we will screen and select  
25  
26 eligible prognostic model studies when the following inclusion criteria are satisfied.  
27  
28

29  
30 1) studies that reported the development or validation multivariable model(s) of AKI  
31  
32 with or without external validation; 2) studies reporting AKI models involving  
33  
34 medical-AKI related critical ill patients and using AKI definitions of Kidney Disease  
35  
36 Improving Global Outcomes (KDIGO),<sup>27</sup> Acute Kidney Injury Network (AKIN),<sup>28</sup>  
37  
38 and Risk, Injury, Failure, Loss, and End-Stage Kidney Disease (RIFLE);<sup>29</sup> 3) studies  
39  
40 that yielded at least two predictors; 4) studies that evaluated or updated the  
41  
42 quantitative measure of model performance of an existing model in an independent  
43  
44 population in terms of overall performance, discriminative ability and calibration of a  
45  
46 certain prediction model. We will exclude conference abstracts, editorials, clinical  
47  
48 case reviews, letters, commentaries, book chapters and surveys. Studies involving  
49  
50 only post-surgical critical ill patients will also be excluded.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Data abstraction

Data extraction will be conducted using a standardised data extraction form by at least two independently reviewers based on the recommendations in the CHARMS checklist.<sup>24</sup> If the needed data are not reported or unclear, the corresponding authors will be contacted for detailed information. The following general study information will be extracted including first author, publication year, model name, publication source and research country. For model development study, we will extract the following specific data: modelling method, method for selection of predictors for inclusion in multivariable modeling combined with criteria used and shrinkage of predictor weights or regression coefficients. For model performance study, measures of calibration and discrimination with confidence intervals will be abstracted. For studies reporting model evaluation, method used for testing model performance will also be abstracted. Besides, the method for treating the missing data involving the prediction model of each eligible study will also be abstracted.

## Critical appraisal

We will critically appraise each included prediction model using the PROBAST technique, a tool to assess risk of bias and applicability of prediction model studies.<sup>30</sup> Based on the checklist of PROBAST, 20 separate questions across 4 domains (participants, predictors, outcome, and analysis) will be asked. Details for the assessment rules are summarized in Table 2. Moreover, we will also use the Modified Downs and Black Checklist and Sackett's Level of Evidence for assessment of risk of

1  
2  
3  
4 bias and methodological quality of included studies.<sup>31 32</sup> Two authors of the research  
5  
6 team will independently assess the risk of bias of the included studies and cross-check  
7  
8 the results. Any discrepancies will be resolved by discussion or by a senior author.  
9  
10

### 11 12 13 14 **Statistical analysis**

15  
16  
17 We will calculate and report descriptive statistics to summarise the characteristics of  
18  
19 the AKI models. For binary or categorical variables, we will calculate frequencies or  
20  
21 percentages, while for continuous variables, means, medians, and interquartile ranges  
22  
23 (IQRs) will be calculated. For the prediction model of AKI developed from different  
24  
25 populations, a random effects meta-analysis will be applied to calculate a summary  
26  
27 estimate for models' performance and calibration. For studies that did not provide  
28  
29 measurements of mean C statistics, we will use a formula to estimate the standard  
30  
31 error of mean C statistic according to the methods proposed by Snell and colleagues.<sup>32</sup>  
32  
33  
34 Due to the relatively small sample size of validation studies for each prediction model,  
35  
36 we will meta-analyse C statistic with its 95% CI using a random-effects model based  
37  
38 on the restricted maximum likelihood (REML) estimation and the  
39  
40 Hartung-Knapp-Sidik-Jonkman (HKSJ) method.<sup>25 33</sup> 95% prediction interval (PI)  
41  
42 integrating the heterogeneity will also be calculated to pool C statistics to predict a  
43  
44 possible range of C statistics of future validation studies. Heterogeneity between  
45  
46 studies will be quantified using the  $I^2$  statistic, defined significant heterogeneity when  
47  
48  $I^2$  statistic more than 50%.<sup>34</sup> To explore the sources of potential heterogeneity, we  
49  
50 will conduct stratified analyses by summarising estimates based on AKI definition  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 (KDIGO vs. AKIN vs. RIFLE), AKI type (any AKI vs. severe AKI or stage 1 AKI vs.  
5  
6 stage 2/3 by KDIGO criteria), window of prediction (first 24h vs. 48-96h) and lack of  
7  
8 evaluation of key characteristics of AKI such as duration, need for renal replacement  
9  
10 therapy, etc (yes vs. no). The potential of publication bias will be assessed by funnel  
11  
12 plots when more than 10 studies are meta-analysed for the prediction model. All  
13  
14 statistical analyses will be carried out using R Statistical Software version 3.2.3(R  
15  
16 Core Team, R Foundation for Statistical Computing, Vienna, Austria) and Stata  
17  
18 version 15.0 (Stata Corporation, College Station, TX, USA).  
19  
20  
21  
22  
23  
24  
25  
26  
27

### 28 **Patient and public involvement**

29  
30 The current study is a systematic review of what is already reported in the literature. It  
31  
32 does not involve patient and public in the design, conduct or reporting of this study.  
33  
34  
35  
36  
37

### 38 **Ethics and dissemination**

39  
40 Ethical approval and patient informed consent are not required because all  
41  
42 information will be abstracted from published literatures. We plan to share our results  
43  
44 with clinicians and publish them in a general or critical care medicine peer- reviewed  
45  
46 journal. We also plan to present our results at critical care international conferences.  
47  
48  
49  
50  
51  
52

### 53 **Amendments**

54  
55  
56 The protocol for this systematic review will be amended when necessary  
57  
58 during the peer-review process.  
59  
60

## DISCUSSION

Although there have been numerous original reports and narrative reviews focusing on the prediction model of AKI,<sup>35-43</sup> several factors may limit the interpretation and application of these prediction models. To the best of our knowledge, this will be the first systematic review that aims to evaluate the published evidence on the prediction models for AKI. This study will provide a clear overview for clinicians to identify some most effective prediction models for AKI among critical ill patients or patients in ICUs. By synthesising data including predictive accuracy such as C statistics across studies, we may get some evidence-based data to stratify disease severity and help inform the clinical management of critical ill patients.

### Strengths and limitations

There will be several strengths of this study. Firstly, we will strictly adhere to the Cochrane Handbook's method recommendations during the conduct and reporting of this systematic review to make the results more reliable.<sup>25 44</sup> The purpose of this study is to achieve high-quality evidence regarding the prediction model of AKI in critical ill patients and provide practice recommendations on its applicability for policy makers. Secondly, we will present a detailed description of the characteristics of the reported prediction models for AKI. Moreover, another important strength is the critical appraisal of prediction models for AKI by using the PROBAST tool.

1  
2  
3  
4 Finally, we will perform a meta-analysis of C statistics for prediction models that are  
5  
6 externally validated in different independent cohorts.  
7  
8  
9

10  
11 There are also limitations to this study. One is that large between study  
12  
13 heterogeneity is expected in the meta-analyses. There may be several potential  
14  
15 sources of heterogeneity including the differences in clinical scenarios, patients'  
16  
17 characteristics, cohort regions or races and statistical methods. However, due to the  
18  
19 small number of development or validation studies, subgroup analyses or meta--  
20  
21 regression analyses cannot be performed.  
22  
23  
24  
25  
26  
27  
28  
29

30 In summary, this study will provide an overall mapping of the available  
31  
32 research on prediction models for AKI in critical ill patients.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Contributorship statement:**

Dr. Zubing Mei and Dr. Danqiong Wang have full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Zubing Mei and Danqiong Wang

Acquisition, analysis, or interpretation of data: Danqiong Wang, Weiwen Zhang, Jian Luo, Honglong Fang, Shanshan Jing, and Zubing Mei.

Drafting of the manuscript: Zubing Mei and Danqiong Wang.

Critical revision of the manuscript for important intellectual content: Danqiong Wang, Weiwen Zhang, Jian Luo, Honglong Fang, Shanshan Jing, and Zubing Mei.

Statistical analysis: Danqiong Wang, Weiwen Zhang and Zubing Mei

Administrative, technical, or material support: All authors.

Study supervision: Zubing Mei and Danqiong Wang

**Competing interests:**

The authors declare that they have no conflict of interest.

**Funding:**

This study was supported by the Commonweal Project of Science and Technology Department of Zhejiang Province (grant no. LGF19H150002), the National Natural Science Foundation of China (grant no. 81774112) and a grant from Siming Scholars from Shuguang Hospital (grant no. SGXZ-201913).

## References

1. Thongprayoon C, Cheungpasitporn W, Chewcharat A, et al. Impact of admission serum ionized calcium levels on risk of acute kidney injury in hospitalized patients. *Scientific reports* 2020;10(1):12316. doi: 10.1038/s41598-020-69405-0 [published Online First: 2020/07/25]
2. Levey AS, James MT. Acute Kidney Injury. *Annals of internal medicine* 2017;167(9):Itc66-itc80. doi: 10.7326/aite201711070 [published Online First: 2017/11/09]
3. Zuk A, Bonventre JV. Acute Kidney Injury. *Annual review of medicine* 2016;67:293-307. doi: 10.1146/annurev-med-050214-013407 [published Online First: 2016/01/16]
4. Zeng X, McMahon GM, Brunelli SM, et al. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. *Clinical journal of the American Society of Nephrology : CJASN* 2014;9(1):12-20. doi: 10.2215/cjn.02730313 [published Online First: 2013/11/02]
5. Varrier M, Forni LG, Ostermann M. Long-term sequelae from acute kidney injury: potential mechanisms for the observed poor renal outcomes. *Critical care (London, England)* 2015;19(1):102. doi: 10.1186/s13054-015-0805-0 [published Online First: 2015/04/19]
6. Soliman IW, Frencken JF, Peelen LM, et al. The predictive value of early acute kidney injury for long-term survival and quality of life of critically ill patients. *Critical care (London, England)* 2016;20(1):242. doi: 10.1186/s13054-016-1416-0 [published Online First: 2016/08/05]
7. Doyle JF, Forni LG. Acute kidney injury: short-term and long-term effects. *Critical care (London, England)* 2016;20(1):188. doi: 10.1186/s13054-016-1353-y [published Online First: 2016/07/05]
8. An JN, Hwang JH, Kim DK, et al. Chronic Kidney Disease After Acute Kidney Injury Requiring Continuous Renal Replacement Therapy and Its Impact on Long-Term Outcomes: A Multicenter Retrospective Cohort Study in Korea. *Critical care medicine* 2017;45(1):47-57. doi: 10.1097/ccm.0000000000002012 [published Online First: 2016/08/27]
9. AKIWG K. Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for acute kidney injury. *Kidney inter* 2012;2(Suppl):1-138.
10. Sandokji I, Greenberg JH. Novel biomarkers of acute kidney injury in children: an update on recent findings. *Current Opinion in Pediatrics* 2020;32(3):354-59.
11. Peng Z-Y. The biomarkers for acute kidney injury: A clear road ahead? *Journal of Translational Internal Medicine* 2016;4(3):95-98.
12. Oh D-J. A long journey for acute kidney injury biomarkers. *Renal Failure* 2020;42(1):154-65.
13. Griffin BR, Gist KM, Faubel S. Current status of novel biomarkers for the diagnosis of acute kidney injury: a historical perspective. *Journal of intensive care medicine* 2020;35(5):415-24.

14. Devarajan P. Emerging biomarkers of acute kidney injury. *Acute Kidney Injury: Karger Publishers* 2007:203-12.
15. Askenazi DJ, Koralkar R, Hundley HE, et al. Urine biomarkers predict acute kidney injury in newborns. *The Journal of pediatrics* 2012;161(2):270-75. e1.
16. Arthur JM, Hill EG, Alge JL, et al. Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery. *Kidney international* 2014;85(2):431-38.
17. Altman DG, Royston P. What do we mean by validating a prognostic model? *Statistics in medicine* 2000;19(4):453-73.
18. Tekdöş Şeker Y, Çukurova Z, Özel Bilgi D, et al. Prognostic Impact of Early Versus Late Initiation of Renal Replacement Therapy Based on Early Warning Algorithm in Critical Care Patients With Acute Kidney Injury. *Therapeutic Apheresis and Dialysis* 2020;24(4):445-52.
19. Lazzeri C, Bonizzoli M, Cianchi G, et al. The prognostic role of peak glycemia and glucose variability in trauma: a single-center investigation. *Acta Diabetologica* 2020:1-5.
20. Haniffa R, Mukaka M, Munasinghe SB, et al. Simplified prognostic model for critically ill patients in resource limited settings in South Asia. *Critical Care* 2017;21(1):250.
21. Wang Q, Tang Y, Zhou J, et al. A prospective study of acute kidney injury in the intensive care unit: development and validation of a risk prediction model. *Journal of translational medicine* 2019;17(1):359.
22. Ferrari F, Puci MV, Ferraro OE, et al. Development and validation of quick Acute Kidney Injury-score (q-AKI) to predict acute kidney injury at admission to a multidisciplinary intensive care unit. *PloS one* 2019;14(6):e0217424.
23. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic reviews* 2015;4(1):1.
24. Moons KG, de Groot JA, Bouwmeester W, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. *PLoS Med* 2014;11(10):e1001744.
25. Debray TP, Damen JA, Snell KI, et al. A guide to systematic review and meta-analysis of prediction model performance. *BMJ (Clinical research ed)* 2017;356:i6460.
26. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Annals of internal medicine* 2015;162(1):W1-W73.
27. Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. *Kidney international supplements* 2012;2(1):1-138.
28. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Critical care (London,*

- England) 2007;11(2):R31. doi: 10.1186/cc5713 [published Online First: 2007/03/03]
29. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Critical care (London, England)* 2004;8(4):R204-12. doi: 10.1186/cc2872 [published Online First: 2004/08/18]
  30. Moons KG, Wolff RF, Riley RD, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. *Annals of internal medicine* 2019;170(1):W1-W33.
  31. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *Journal of Epidemiology & Community Health* 1998;52(6):377-84.
  32. Sackett DL, Richardson WS, Straus SE, et al. *Evidence-based Medicine: How to Practice and Teach EBM*: Churchill Livingstone 2000.
  33. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. *BMC medical research methodology* 2014;14(1):25.
  34. Rücker G, Schwarzer G, Carpenter JR, et al. Undue reliance on I<sup>2</sup> in assessing heterogeneity may mislead. *BMC medical research methodology* 2008;8(1):79.
  35. Porter CJ, Moppett IK, Juurlink I, et al. Acute and chronic kidney disease in elderly patients with hip fracture: prevalence, risk factors and outcome with development and validation of a risk prediction model for acute kidney injury. *BMC nephrology* 2017;18(1):20.
  36. Kalisvaart M, Schlegel A, Umbro I, et al. The AKI Prediction Score: a new prediction model for acute kidney injury after liver transplantation. *HPB* 2019;21(12):1707-17.
  37. Tomašev N, Glorot X, Rae JW, et al. A clinically applicable approach to continuous prediction of future acute kidney injury. *Nature* 2019;572(7767):116-19.
  38. Motwani SS, McMahon GM, Humphreys BD, et al. Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. *Journal of Clinical Oncology* 2018;36(7):682.
  39. Koyner JL, Carey KA, Edelson DP, et al. The development of a machine learning inpatient acute kidney injury prediction model. *Critical care medicine* 2018;46(7):1070-77.
  40. Laszczynska O, Severo M, Azevedo A. Electronic medical record-based predictive model for acute kidney injury in an acute care hospital. *Studies in health technology and informatics*, vol 228, p 810-812 2016

- 1  
2  
3 41. Pannu N, Graham M, Klarenbach S, et al. A new model to predict acute kidney  
4 injury requiring renal replacement therapy after cardiac surgery. CMAJ  
5 2016;188(15):1076-83.  
6  
7 42. Piñana JL, Perez-Pitarch A, Garcia-Cadenas I, et al. A time-to-event model for  
8 acute kidney injury after reduced-intensity conditioning stem cell  
9 transplantation using a tacrolimus-and sirolimus-based graft-versus-host  
10 disease prophylaxis. Biology of Blood and Marrow Transplantation  
11 2017;23(7):1177-85.  
12  
13 43. Tsai TT, Patel UD, Chang TI, et al. Validated contemporary risk model of acute  
14 kidney injury in patients undergoing percutaneous coronary interventions:  
15 insights from the National Cardiovascular Data Registry Cath - PCI Registry.  
16 Journal of the American Heart Association 2014;3(6):e001380.  
17  
18 44. Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic  
19 reviews of interventions: John Wiley & Sons 2019.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Tables and legends

**Table 1.** Primary elements for formulating study purpose, search strategy, inclusion and exclusion criteria for the study according to the following PICOTS guidance

<b>Item</b>	<b>Definition</b>
Population	Patients who were critically ill
Intervention	Any prediction model to predict the risk of acute kidney injury (AKI) in patients with critical illness, to distinguish critical ill patients with poor outcome (who will develop AKI), or to aid in clinical decision making in acute care, planning therapeutic intervention and monitoring treatment response
Comparator	Not applicable
Outcomes	AKI reported by prediction models
Timing	Predictive variables measured at any timepoint during the clinical course of the disease; no specific limitation applied in prediction horizon
Setting	Patients with critical illness who were admitted to hospital, treated in intensive care unit (ICU), or emergency department

1  
2  
3  
4 **Table 2.** Twenty key questions assessing the risk of bias for 4 domains of participants,  
5  
6 predictors, outcome and analysis.  
7  
8

---

9 **Domain 2: Participants**  
10

---

11 1.1 Were appropriate data sources used, e.g., cohort, RCT, or nested case-control  
12 study data?  
13  
14

15 1.2 Were all inclusions and exclusions of participants appropriate?  
16  
17

---

18 **Domain 2: Predictors**  
19

---

20 2.1 Were predictors defined and assessed in a similar way for all participants?  
21  
22

23 2.2 Were predictor assessments made without knowledge of outcome data?  
24  
25

26 2.3 Are all predictors available at the time the model is intended to be used?  
27  
28

---

29 **Domain 3: Outcome**  
30

---

31 3.1 Was the outcome determined appropriately?  
32  
33

34 3.2 Was a prespecified or standard outcome definition used?  
35  
36

37 3.3 Were predictors excluded from the outcome definition?  
38  
39

40 3.4 Was the outcome defined and determined in a similar way for all participants?  
41  
42

43 3.5 Was the outcome determined without knowledge of predictor information?  
44  
45

46 3.6 Was the time interval between predictor assessment and outcome determination  
47 appropriate?  
48  
49

---

50 **Domain 4: Analysis**  
51

---

52 4.1 Were there a reasonable number of participants with the outcome?  
53  
54

55 4.2 Were continuous and categorical predictors handled appropriately?  
56  
57

58 4.3 Were all enrolled participants included in the analysis?  
59  
60

---

---

1  
2  
3  
4 4.4 Were participants with missing data handled appropriately?  
5  
6

7 4.5 Was selection of predictors based on univariable analysis avoided?  
8

9 4.6 Were complexities in the data (e.g., censoring, competing risks, sampling of  
10 control participants) accounted for appropriately?  
11  
12

13  
14 4.7 Were relevant model performance measures evaluated appropriately?  
15  
16

17 4.8 Were model overfitting and optimism in model performance accounted for?  
18

19 4.9 Do predictors and their assigned weights in the final model correspond to the  
20 results from the reported multivariable analysis?  
21  
22  
23

---



# Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preorting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

		Reporting Item	Page Number
<b>Title</b>			
Identification	<a href="#">#1a</a>	Identify the report as a protocol of a systematic review	1
Update	<a href="#">#1b</a>	If the protocol is for an update of a previous systematic review, identify as such	n/a
<b>Registration</b>			
	<a href="#">#2</a>	If registered, provide the name of the registry (such as PROSPERO) and registration number	5
<b>Authors</b>			
Contact	<a href="#">#3a</a>	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	<a href="#">#3b</a>	Describe contributions of protocol authors and identify the	2-3

guarantor of the review

## Amendments

<a href="#">#4</a>	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	n/a
--------------------	---	-----

## Support

Sources	<a href="#">#5a</a>	Indicate sources of financial or other support for the review	2
Sponsor	<a href="#">#5b</a>	Provide name for the review funder and / or sponsor	2
Role of sponsor or funder	<a href="#">#5c</a>	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	3

## Introduction

Rationale	<a href="#">#6</a>	Describe the rationale for the review in the context of what is already known	7-8
Objectives	<a href="#">#7</a>	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	8

## Methods

Eligibility criteria	<a href="#">#8</a>	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	10
Information sources	<a href="#">#9</a>	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	9
Search strategy	<a href="#">#10</a>	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	9
Study records - data management	<a href="#">#11a</a>	Describe the mechanism(s) that will be used to manage records and data throughout the review	10
Study records -	<a href="#">#11b</a>	State the process that will be used for selecting studies (such	10

1	selection process		as two independent reviewers) through each phase of the	
2			review (that is, screening, eligibility and inclusion in meta-	
3			analysis)	
4				
5	Study records -	<a href="#">#11c</a>	Describe planned method of extracting data from reports	11
6	data collection		(such as piloting forms, done independently, in duplicate),	
7	process		any processes for obtaining and confirming data from	
8			investigators	
9				
10				
11				
12	Data items	<a href="#">#12</a>	List and define all variables for which data will be sought	11
13			(such as PICO items, funding sources), any pre-planned data	
14			assumptions and simplifications	
15				
16				
17	Outcomes and	<a href="#">#13</a>	List and define all outcomes for which data will be sought,	12
18	prioritization		including prioritization of main and additional outcomes, with	
19			rationale	
20				
21				
22				
23	Risk of bias in	<a href="#">#14</a>	Describe anticipated methods for assessing risk of bias of	11-12
24	individual studies		individual studies, including whether this will be done at the	
25			outcome or study level, or both; state how this information will	
26			be used in data synthesis	
27				
28				
29				
30	Data synthesis	<a href="#">#15a</a>	Describe criteria under which study data will be quantitatively	12
31			synthesised	
32				
33	Data synthesis	<a href="#">#15b</a>	If data are appropriate for quantitative synthesis, describe	12
34			planned summary measures, methods of handling data and	
35			methods of combining data from studies, including any	
36			planned exploration of consistency (such as I <sup>2</sup> , Kendall's $\tau$ )	
37				
38				
39				
40	Data synthesis	<a href="#">#15c</a>	Describe any proposed additional analyses (such as	12-13
41			sensitivity or subgroup analyses, meta-regression)	
42				
43				
44	Data synthesis	<a href="#">#15d</a>	If quantitative synthesis is not appropriate, describe the type	12-13
45			of summary planned	
46				
47				
48	Meta-bias(es)	<a href="#">#16</a>	Specify any planned assessment of meta-bias(es) (such as	12-13
49			publication bias across studies, selective reporting within	
50			studies)	
51				
52				
53	Confidence in	<a href="#">#17</a>	Describe how the strength of the body of evidence will be	11-12
54	cumulative		assessed (such as GRADE)	
55	evidence			
56				
57				
58				
59				
60				

1 The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative  
2 Commons Attribution License CC-BY. This checklist was completed on 31. March 2021 using  
3 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with  
4 [Penelope.ai](#)  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only